| Hi5 |
* This study has finished * |
| Full title: |
5HIAA as a marker for anti-vascular activity: change in serum 5HIAA in patients with advanced colorectal cancer receiving diclofenac or chemotherapy, and in control subjects without cancer receiving diclofenac |
| Cancer type: |
Colorectal |
| Status: |
Closed (29 participants recruited) |
| Brief description:
|
This was a pilot study where scientists and clinicians explored the clinical application of blood markers (serum 5HIAA) associated with endothelial damage during anti-cancer therapy. The study involves cancer patients who are planned to receive chemotherapy and a group of healthy volunteers. |
| Sites: |
Auckland |
| Lead Investigator: |
Professor Michael Findlay |
| Contact: |
Sarah Benge (s.benge@auckland.ac.nz) |
| Sponsor: |
University of Auckland |
| Funder: |
Genesis Oncology Trust |
| Trial Registry reference: |
ACTRN12605000459628 (click for more details) |
| Ethics number: |
AKY/04/11/315 |
| Publications: |
|
